InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-21 | 2026-04-27 | Purcell Michael J. | Director | Purchase | 1.25M | $0.04 | $50K | 1.25M | View ↗ | |
| 2026-04-21 | 2026-04-27 | LoPriore Vincent S | Director & Executive Chairman | Purchase | 5.00M | $0.04 | $200K | 5.00M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenues | — | — | — | $0 |
| Research and development | $446K-96.2% | $11.8M-66.8% | $35.6M+7.1% | $33.3M |
| General and administrative | $3.3M-55.8% | $7.5M-22.0% | $9.6M-7.1% | $10.3M |
| Asset impairment loss | $403K | — | — | $1.9M |
| Total operating expenses | $4.2M-78.5% | $19.3M-60.1% | $48.4M+6.5% | $45.5M |
| Loss from operations | -$4.2M+78.5% | -$19.3M+60.1% | -$48.4M-6.5% | -$45.5M |
| Interest expense, net | -$24K+98.0% | -$1.2M-13078.2% | -$9K | — |
| Write-off related party note receivable | -$600K | — | — | — |
| Change in fair value of contingent consideration and derivative financial instruments | -$4.1M-153.8% | $7.6M+965.9% | -$878K-311.5% | $415K |
| Inducement expense | -$2.6M | — | — | — |
| Loss before income taxes | -$8.3M+48.8% | -$16.2M+67.2% | -$49.3M-9.4% | -$45.1M |
| Income tax benefit (expense) | $3.0M | — | $409K-85.8% | $2.9M |
| Net loss | -$8.3M+37.3% | -$13.2M+73.0% | -$48.9M-15.9% | -$42.2M |
| Weighted-average common shares outstanding basic | $9.4M+7556.5% | $123K+54.7% | $79K-97.9% | $3.8M |
| Weighted-average common shares outstanding diluted | $9.4M+7556.5% | $123K+54.7% | $79K-97.9% | $3.8M |
| Net loss per common share basic | -$0.88+99.2% | -$107.35+82.6% | -$616.07-5077.1% | -$11.9 |
| Net loss per common share diluted | -$0.88+99.2% | -$107.35+82.6% | -$616.07-5077.1% | -$11.9 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
Hepion Pharmaceuticals appoints Kaouthar Lbiati as interim CEO
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
Hepion Pharmaceuticals receives delisting notification from Nasdaq